248 related articles for article (PubMed ID: 29103154)
1. Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease.
Weilnau JN; Carcella MA; Miner KM; Bhatia TN; Hutchison DF; Pant DB; Nouraei N; Leak RK
Brain Struct Funct; 2018 Apr; 223(3):1255-1273. PubMed ID: 29103154
[TBL] [Abstract][Full Text] [Related]
2. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
[TBL] [Abstract][Full Text] [Related]
3. A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study.
Healy-Stoffel M; Ahmad SO; Stanford JA; Levant B
J Neurosci Methods; 2012 Sep; 210(2):187-94. PubMed ID: 22850559
[TBL] [Abstract][Full Text] [Related]
4. Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Brown AR; Hu B; Antle MC; Teskey GC
Exp Neurol; 2009 Nov; 220(1):162-70. PubMed ID: 19703443
[TBL] [Abstract][Full Text] [Related]
5. Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
Mendes-Pinheiro B; Soares-Cunha C; Marote A; Loureiro-Campos E; Campos J; Barata-Antunes S; Monteiro-Fernandes D; Santos D; Duarte-Silva S; Pinto L; José Salgado A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768962
[TBL] [Abstract][Full Text] [Related]
6. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
7. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
8. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.
Ip CW; Beck SK; Volkmann J
J Neural Transm (Vienna); 2015 Dec; 122(12):1633-43. PubMed ID: 26290125
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Harkavyi A; Abuirmeileh A; Lever R; Kingsbury AE; Biggs CS; Whitton PS
J Neuroinflammation; 2008 May; 5():19. PubMed ID: 18492290
[TBL] [Abstract][Full Text] [Related]
11. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.
Walsh S; Mnich K; Mackie K; Gorman AM; Finn DP; Dowd E
Brain Res Bull; 2010 Apr; 81(6):543-8. PubMed ID: 20097273
[TBL] [Abstract][Full Text] [Related]
12. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Fletcher EJR; Moon LDF; Duty S
BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
[TBL] [Abstract][Full Text] [Related]
13. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
14. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
16. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
17. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
18. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
19. Graded 6-OHDA-induced dopamine depletion in the nigrostriatal pathway evokes progressive pathological neuronal activities in the subthalamic nucleus of a hemi-parkinsonian mouse.
Park SE; Song KI; Kim H; Chung S; Youn I
Behav Brain Res; 2018 May; 344():42-47. PubMed ID: 29452192
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]